In a mouse study, researchers found that zolpidem (Ambien), a common sleep aid, could prevent the brain from effectively ...

Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly treatment at home in 15 seconds ... s disease ...

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Consistent with the approach taken by other alternative payment models, GUIDE frames the emergency department as a negative ...